Cell Free DNA 10ml Reduced Patient Risk Early Disease Detection Cancer
Price:
Negotiation
MOQ:
100
Delivery Time:
Negotiable
Brand:
Orsin
Product Description
Cell Free DNA 10ml Reduced Patient Risk Early Disease Detection Cancer
| Attribute | Value |
|---|---|
| Color | Purple |
| Application | Early Disease Detection |
| Material | Glass and pet |
| Advantage | Sterile And Safe Compatible With Equipment |
| Trait | Cancer |
| Capacity | 10ml |
Orsin Medical Technology - Cell-Free DNA (cfDNA) Extraction & Analysis Solutions
Product Description
Orsin Medical Technology delivers high-efficiency, ultra-sensitive cfDNA extraction and detection products, designed for liquid biopsy, non-invasive prenatal testing (NIPT), cancer early screening, and transplant monitoring.
Key Advantages
- ✔ Ultra-Low Input Compatibility - Reliable extraction even from minimal samples (e.g., 1mL plasma)
- ✔ High Recovery Rate & Minimal Fragmentation - Proprietary technology preserves short fragments (~150-200bp), ensuring optimal ctDNA/fetal DNA capture
- ✔ Automation-Ready - Supports high-throughput processing for clinical and research applications
- ✔ Multi-Platform Compatibility - Seamless integration with qPCR, ddPCR, NGS, and other downstream analyses
Applications
- Cancer Monitoring - Dynamic tumor burden tracking & treatment response
- NIPT - Safe, accurate fetal genetic screening
- Transplant Rejection Surveillance - Donor-derived cfDNA (dd-cfDNA) detection
Purer cfDNA, Stronger Diagnostics — Orsin Medical Technology, Powering Precision Medicine
Technical Specifications & Competitive Advantages
Core Performance Parameters
| Parameter | Orsin Technology | Industry Standard (Typical) |
|---|---|---|
| Input Volume | 0.5-2 mL plasma (ultra-low input compatible) | 3-10 mL plasma |
| Yield Efficiency | >85% recovery (50-200bp fragments) | 60-75% recovery |
| Fragment Retention | Optimized for 50-300bp (critical for ctDNA) | Bias toward >150bp |
| Process Time | 30 min (semi-automated) / 96 samples in 2h | 2-4 hours (manual) |
| Inhibitor Removal | PCR/NGS-compatible (A260/A280: 1.8-2.0) | Frequent heparin/hemoglobin interference |
Key Differentiators vs Competitors
| Feature | Orsin Advantage | Common Limitations Elsewhere |
|---|---|---|
| Short-DNA Capture | Proprietary silica beads + size-selection | Loss of |
| Automation | Fully compatible with KingFisher/Hamilton | Manual column-based kits |
| Multiplexing | Simultaneous extraction of cfDNA+exosomes* | cfDNA-only isolation |
| Cost per Sample | ~$15 (high-throughput) | $20-50 (competitor kits) |
Downstream Compatibility
- NGS:
- ddPCR: CV
- Methylation Analysis: Preserves epigenetic signatures
Validation Data
- LoD: 0.01% mutant allele frequency (MAF) in 5ng cfDNA
- Reproducibility: 98% concordance in 500+ clinical samples
At Orsin Medical Technology, we combine cutting-edge innovation with clinical practicality to redefine liquid biopsy standards. Our cfDNA solutions are:
Validated - Rigorously tested in CAP/CLIA environments
Scalable - From research to high-volume clinical labs
Evolving - Continuous optimization for emerging biomarkers (e.g., fragmentomics, methylation patterns)
Validated - Rigorously tested in CAP/CLIA environments
Scalable - From research to high-volume clinical labs
Evolving - Continuous optimization for emerging biomarkers (e.g., fragmentomics, methylation patterns)
Partner with us to unlock the full potential of liquid biopsy. Contact our technical team for assay validation protocols & application-specific protocols.
Similar Products
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.
Company
Shanghai Orsin Medical Technology Co., Ltd.
Location
Building A, No.599 Wanhua Road, Zhelin Town, Fengxian Area, Shanghai, China
Contact Person
Niki Pan